Bibliographic Details
| Title: |
Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases |
| Authors: |
Qiuyi Zhang MD, Xiaofeng Lan MD, Jiayi Huang MD, Xiaofeng Xie MD, Liping Chen MD, Lin Song MD, Xue Bai MD, Xuelian Chen PhD, Haiman Jing PhD, Caiwen Du PhD |
| Source: |
Technology in Cancer Research & Treatment, Vol 23 (2024) |
| Publisher Information: |
SAGE Publishing, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Objective This real-world study aimed to investigate the efficacy and safety of palbociclib plus endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the real world in a Chinese population. Methods The clinical data of consecutively enrolled patients from the Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, and the University of Hong Kong - Shenzhen Hospital were collected. Progression-free survival curves were generated using log-rank tests with the Kaplan-Meier method. Univariate and multivariate logistic regression analyses were performed to identify the factors affecting progression-free survival. Results In total, 118 patients were enrolled, including 6 patients with brain metastases. At the last follow-up date, the median progression-free survival was 16.8 months (95% confidence interval, 11.1-22.5), with the 6-month and 12-month progression-free survival rates of 77.1% and 57.6%, respectively. The disease control rate and the intracranial disease control rate were 82.2% and 50%, respectively. A longer progression-free survival was observed for patients with the following characteristics: treatment-naive; without hepatic metastasis; sensitive to previous endocrine therapy and harboring fewer metastatic sites. The multivariate logistic regression analysis demonstrated that treatment lines and exposure to palliative chemotherapy were independent influencing factors of progression-free survival. Conclusions Palbociclib plus endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer was effective and well-tolerated, even in patients with brain metastases. More benefits were observed in frontline therapy, chemotherapy-naive, and endocrine therapy–sensitive patients with fewer metastatic sites. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1533-0338
15330338 |
| Relation: |
https://doaj.org/toc/1533-0338 |
| DOI: |
10.1177/15330338231206986 |
| Access URL: |
https://doaj.org/article/75c5365ae965468a8685b9517cecd169 |
| Accession Number: |
edsdoj.75c5365ae965468a8685b9517cecd169 |
| Database: |
Directory of Open Access Journals |
